vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and G III APPAREL GROUP LTD (GIII). Click either name above to swap in a different company.
G III APPAREL GROUP LTD is the larger business by last-quarter revenue ($988.6M vs $598.7M, roughly 1.7× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 8.2%, a 32.7% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs -9.0%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $-106.4M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 13.7%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
G III Apparel Group is a global fashion company that designs, sources, manufactures, markets and distributes apparel, footwear, and accessories under a range of owned and licensed well-known brands. It serves department stores, specialty retailers, and e-commerce platforms across North America, Europe, and other key global markets, catering to casual, sportswear, and premium fashion consumer segments.
EXEL vs GIII — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $988.6M |
| Net Profit | $244.5M | $80.6M |
| Gross Margin | 95.6% | 38.6% |
| Operating Margin | 39.3% | 11.4% |
| Net Margin | 40.8% | 8.2% |
| Revenue YoY | 5.6% | -9.0% |
| Net Profit YoY | 74.8% | -29.8% |
| EPS (diluted) | $0.89 | $1.84 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $988.6M | ||
| Q3 25 | $568.3M | $613.3M | ||
| Q2 25 | $555.4M | $583.6M | ||
| Q1 25 | $566.8M | $839.5M | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $539.5M | $644.8M | ||
| Q2 24 | $637.2M | $609.7M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $80.6M | ||
| Q3 25 | $184.8M | $10.9M | ||
| Q2 25 | $159.6M | $7.8M | ||
| Q1 25 | $139.9M | $48.8M | ||
| Q4 24 | — | $114.8M | ||
| Q3 24 | $118.0M | $24.2M | ||
| Q2 24 | $226.1M | $5.8M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 38.6% | ||
| Q3 25 | 96.6% | 40.8% | ||
| Q2 25 | 96.5% | 42.2% | ||
| Q1 25 | 96.5% | 39.5% | ||
| Q4 24 | — | 39.8% | ||
| Q3 24 | 96.8% | 42.8% | ||
| Q2 24 | 97.2% | 42.5% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 11.4% | ||
| Q3 25 | 37.6% | 2.7% | ||
| Q2 25 | 33.6% | 1.5% | ||
| Q1 25 | 28.8% | 8.5% | ||
| Q4 24 | — | 15.3% | ||
| Q3 24 | 25.2% | 6.4% | ||
| Q2 24 | 43.3% | 2.2% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 8.2% | ||
| Q3 25 | 32.5% | 1.8% | ||
| Q2 25 | 28.7% | 1.3% | ||
| Q1 25 | 24.7% | 5.8% | ||
| Q4 24 | — | 10.6% | ||
| Q3 24 | 21.9% | 3.8% | ||
| Q2 24 | 35.5% | 1.0% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $1.84 | ||
| Q3 25 | $0.65 | $0.25 | ||
| Q2 25 | $0.55 | $0.17 | ||
| Q1 25 | $0.47 | $1.00 | ||
| Q4 24 | — | $2.55 | ||
| Q3 24 | $0.40 | $0.53 | ||
| Q2 24 | $0.77 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $184.1M |
| Total DebtLower is stronger | — | $6.5M |
| Stockholders' EquityBook value | $2.2B | $1.8B |
| Total Assets | $2.8B | $2.8B |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $184.1M | ||
| Q3 25 | $791.1M | $301.8M | ||
| Q2 25 | $1.0B | $257.8M | ||
| Q1 25 | $1.1B | $181.4M | ||
| Q4 24 | — | $104.7M | ||
| Q3 24 | $1.2B | $414.8M | ||
| Q2 24 | $1.0B | $508.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $6.5M | ||
| Q3 25 | — | $6.9M | ||
| Q2 25 | — | $6.8M | ||
| Q1 25 | — | $3.0M | ||
| Q4 24 | — | $213.9M | ||
| Q3 24 | — | $402.5M | ||
| Q2 24 | — | $402.7M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $1.8B | ||
| Q3 25 | $2.0B | $1.7B | ||
| Q2 25 | $2.1B | $1.7B | ||
| Q1 25 | $2.2B | $1.7B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | $2.3B | $1.5B | ||
| Q2 24 | $2.1B | $1.5B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $2.8B | ||
| Q3 25 | $2.7B | $2.7B | ||
| Q2 25 | $2.8B | $2.4B | ||
| Q1 25 | $2.9B | $2.5B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | $3.0B | $2.7B | ||
| Q2 24 | $2.8B | $2.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.27× | ||
| Q2 24 | — | 0.26× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $-97.3M |
| Free Cash FlowOCF − Capex | $332.4M | $-106.4M |
| FCF MarginFCF / Revenue | 55.5% | -10.8% |
| Capex IntensityCapex / Revenue | 0.2% | 0.9% |
| Cash ConversionOCF / Net Profit | 1.36× | -1.21× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $367.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $-97.3M | ||
| Q3 25 | $49.0M | $75.1M | ||
| Q2 25 | $211.4M | $93.8M | ||
| Q1 25 | $240.3M | $333.4M | ||
| Q4 24 | — | $-111.8M | ||
| Q3 24 | $271.3M | $49.3M | ||
| Q2 24 | $119.5M | $45.5M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $-106.4M | ||
| Q3 25 | $46.2M | $64.7M | ||
| Q2 25 | $208.5M | $85.7M | ||
| Q1 25 | $236.3M | $323.7M | ||
| Q4 24 | — | $-120.3M | ||
| Q3 24 | $263.1M | $38.8M | ||
| Q2 24 | $113.0M | $32.8M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | -10.8% | ||
| Q3 25 | 8.1% | 10.6% | ||
| Q2 25 | 37.5% | 14.7% | ||
| Q1 25 | 41.7% | 38.6% | ||
| Q4 24 | — | -11.1% | ||
| Q3 24 | 48.8% | 6.0% | ||
| Q2 24 | 17.7% | 5.4% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 0.9% | ||
| Q3 25 | 0.5% | 1.7% | ||
| Q2 25 | 0.5% | 1.4% | ||
| Q1 25 | 0.7% | 1.2% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | 1.5% | 1.6% | ||
| Q2 24 | 1.0% | 2.1% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | -1.21× | ||
| Q3 25 | 0.27× | 6.86× | ||
| Q2 25 | 1.32× | 12.09× | ||
| Q1 25 | 1.72× | 6.83× | ||
| Q4 24 | — | -0.97× | ||
| Q3 24 | 2.30× | 2.04× | ||
| Q2 24 | 0.53× | 7.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
GIII
| Proprietary Brands | $498.1M | 50% |
| Licensed Brands | $479.2M | 48% |
| Retail Segment | $45.7M | 5% |
